Canonic was established in early 2019 as a subsidiary of Evogene – a world-renowned computational biology powerhouse – with the goal of innovating and bringing advanced scientific methods to the medical cannabis industry. We strive to produce good and accurate cannabis products using unique technology and development processes that have never been seen before.
Dr. Arnon Heyman is the CEO of Canonic Ltd. Dr. Heyman has previously served as VP and GM of Evogene’s Ag-Seeds division managing all plant genetics activities and related collaborations. Prior to Evogene, Dr. Heyman served as CTO of BondX Technologies Ltd. from 2009-2014.
Dr. Heyman holds a PhD. In Biotechnology from the Hebrew University in Jerusalem (2008) and a MBA from the College of Management (2015).